Centessa Pharmaceuticals PLC ADR
Price & Volume
Stats
See more52W Range | $6.65-$18.97 |
Market Cap | $2.2B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $6.8M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.52 |
News
See moreYahoo Finance • last year
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Yahoo Finance • last year
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Yahoo Finance • last year
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
Yahoo Finance • last year
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
About
CEO | Dr. Saurabh Saha M.D., Ph.D. |
CFO | Mr. John J. Crowley CPA |
Address | 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 76 |
